The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...

The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce ...

With the new use, Dupixent becomes the first biologic treatment ... It will be used as an add-on maintenance treatment for adults whose COPD is not well controlled with inhalers. The drug (generic ...

Inhalers used to treat symptoms of respiratory disease can be potent sources of greenhouse gases. Drugmakers are planning to ...

Low climate-impact corticosteroid inhalers are as effective as high climate impact inhalers for COPD and asthma outcomes, per ...

“We have good medications for COPD and most patients respond and their ... according to findings published in the New England Journal of Medicine. While about 68 percent of patients on ...

The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM: US, France, Germany, Italy, Spain, ...

The frequency of usage of rescue inhalers is a very good tool to measure how the COPD is progressing. Other questions that need to be asked are whether the patient has new associated symptoms and ...

AstraZeneca recently announced the completion of clinical studies for a next-generation propellant (NGP) version of its chronic obstructive pulmonary disease (COPD) inhaler, Breztri. This new ...

New reports reveal the most commonly prescribed inhaler in the U.S. may actually ... with chronic obstructive pulmonary disease or COPD for short, as well as other lung diseases.

Right now the new inhaler propellant costs more ... for a propellant with 99.9% lower emissions for its COPD metered-dose maintenance inhaler, Breztri. The company plans to file for regulatory ...